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Abstract
HIV-1 exposure causes several dramatic unbalances in the immune system homeostasis. Here, we
will focus on the paradox whereby CD4 specific autoimmune responses, which are expected to
contribute to the catastrophic loss of most part of the T helper lymphocyte subset in infected
patients, may display the characteristics of an unconventional protective immunity in individuals
naturally resistant to HIV-1 infection. Reference to differences in fine epitope mapping of these two
oppositely polarized outcomes will be presented, with particular reference to partially or totally
CD4-gp120 complex-specific antibodies. The fine tuning of the anti-self immune response to the
HIV-1 receptor may determine whether viral exposure will result in infection or, alternatively,
protective immunity.
Along this line, an efficacious anti-HIV strategy can rely on the active (i.e., through immunization)
or passive targeting of cryptic epitopes of the CD4-gp120 complex, including those harboured
within the CD4 molecule. Such epitopes are expected to be safe from genetic drift and thus allow
for broad spectrum of efficacy. Moreover, since these epitopes are not routinely exposed in
uninfected individuals, they are expected to become targets of neutralizing antibodies or other
specifically designed molecules only after viral exposure, with a predictable low impact in terms of
potentially harmful anti-CD4 self-reactivity.
The experimentum naturae of naturally resistant individuals indicates a strategy to design innovative
strategies to neutralize HIV-1 by acting on the sharp edge between harmful and protective self-
reactivity.
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1. The paradox of CD4 T cell depletion in HIV-1 
infection
Immune abnormalities are common features of both HIV
infection and autoimmune diseases. The depletion of the
CD4 T lymphocytes is the hallmark of the progression of
HIV infection and, in the absence of antiviral treatment,
the main contributor to the development of opportunistic
infections and ultimately to the death of the majority of
infected patients.
CD4 T lymphocytes physiologically play a central role in
orchestrating the whole immune response, including the
humoral and the cellular arms of acquired immunity
against pathogens. Thus, it could be theoretically expected
that a profound inhibition of immune cell activation
would go together with CD4 cell death in HIV-1 infected
persons. In contrast, levels of immune activation, as
assessed by proportions of CD38+ DR+ T cells and serum
concentrations of β2 microglobulin are closely correlated
with disease progression and actually appear more accu-
rate disease predictors than CD4 cell counts or viral load.
HIV-1 infection leads to sustained activation of many key
components of the immune system even in the very early
stages and this is likely a fundamental mechanism for the
ultimate collapse of immunity [1]. On the other hand, the
natural host of SIV infection, sooty mangabeys, do not
experience immune activation despite high levels of viral
replication and this condition is associated with the
absence of disease [2]. Similarly, the majority of HIV-2-
infected subjects who remain free from HIV-induced
immune suppression show negligible immune activation,
whereas immune activation in progressor subjects with
HIV-2 is comparable to that seen in HIV-1 infection [3]. In
this scenario, the immune response to self antigens has
often been alleged to play a detrimental role, by acting as
an effector mechanism which indeed could explain how
the relatively limited numbers of CD4 T cells actually
infected by HIV-1 could bring to the catastrophic loss of
this cell type during disease progression.
In particular, autoimmunity could contribute to impair
CD4 T cell functions in HIV-1 infected persons via reactiv-
ity to the CD4 molecule itself. Indeed, in a pilot study by
Keiser et al. [4] and in our own experience (S. Burastero,
personal observation) anti-CD4 antibodies were found 90
to 540 days before the appearance of antibodies to HIV-1
in exposed individuals, suggesting that they may play a
detrimental role since the first stages of HIV-1 infection. A
recent study mapped the earliest anti-gp120 binding anti-
body responses to include the third variable region (V3)
and reported that antibodies specific for CD4-induced
epitopes, the CD4 binding site, and the membrane proxi-
mal external region of gp41 were not identified among
early anti-Env responses [5]. Moreover, Davis et al.
reported that high-titre, broadly reactive V3-specific anti-
bodies are among the first to be elicited during acute and
early HIV-1 infection and following vaccination. How-
ever, these antibodies lacked neutralizing potency against
primary HIV-1 viruses, which effectively shield V3 from
antibody binding to the functional Env trimer [6]. In this
context, dedicated parallel studies are needed to accu-
rately define the timing of appearance of anti-CD4 anti-
bodies, particularly to gp120-induced epitope, as
compared to anti-Env antibodies
2. Mechanisms for breaking of tolerance 
following HIV-1 exposure
2a) Cell death and apoptosis
Several mechanisms were studied, which could support
the development of autoimmunity in HIV-1 infected per-
sons. Oswald-Ritchter at al. proposed a specific suscepti-
bility of regulatory T cells to HIV-1 infection [7] whereas
Rawson et al. [8] focused on the increased tendency of
CD4 T lymphocytes from infected individuals to undergo
activation-induced death or apoptosis and demonstrated
the subsequent presentation of remarkable amounts of
self-epitopes. This second mechanism was found capable
to break tolerance and trigger cytotoxic T cell-mediated
autoreactivity towards several autoantigens, such as
myosin, vimentin and actin [8], promoting the formation
of autoreactive CD8 T cells. Apoptosis is an ordered state
of cell death in which the structural components of the
cell are carefully disassembled by the activity of a unique
set of proteolytic enzymes, notably members of the cas-
pase family [8]. The self-proteins broken down by cas-
pases in a multitude of apoptotic cells can also prime
cytotoxic T lymphocytes (CTLs) through subsequent pro-
teasomal digestion and cross-presentation. Thus, the mas-
sive death and destruction of lymphocytes in HIV-1
infection could break tolerance to self-peptides and per-
mits the generation of autoreactive CTLs responding to
the cleavage products of apoptotic cells.
2b) Immunodeficiency and autoimmune phenomena in 
lentiviral infection of non-human primates
Both SIV-infected Rhesus macaques and Sooty Manga-
beys, species from Africa are naturally infected with SIV,
yet they do not display any detectable signs of immune
deficiency or autoimmunity. On this basis, they have been
used as models to explore the possible mechanism under-
lying the generation of autoimmune phenomena in HIV-
1 infected humans [9]. In one crucial observation based
on ex vivo CD4 T cell depletion, the availability of acti-
vated CD4+ T cells, rather than immune control of SIV
replication, appeared the main determinant of viral load
during natural SIV infection of Sooty Mangabeys [10].
Moreover, in blood and tissues of rhesus macaques inoc-
ulated with derivatives of the pathogenic SIVsmE543-3 or
SIVmac239, phenotypic analysis of CD4(+) T cells dem-
onstrated two patterns of depletion, primarily affecting
either naïve or memory CD4(+) T cells [11], respectively.
In this experimental setting, progressive decline of totalJournal of Translational Medicine 2009, 7:101 http://www.translational-medicine.com/content/7/1/101
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CD4(+) T cells was observed only in those macaques with
naïve CD4(+) T cell depletion and the level of autoreactive
antibodies correlated with the extent of naive CD4(+) T
cell depletion. These results suggest an important role of
autoreactive antibodies and of naïve T cells in the CD4(+)
T cell decline observed during progression to AIDS [11].
2c) Cryptic epitopes and inter-molecular help can 
generate anti-CD4 auto-reactiviy
An autoimmune cytotoxic T-cell response to the CD4
molecule was described in HIV-1 positive patients
[12,13]. The unveiling of cryptic epitopes following inter-
nalization of CD4 in complex with gp120 was proposed
to explain the pathogenesis of this phenomenon [14,15].
A further in vivo proof of principle of the importance of
this mechanism was provided by Abulafia-Laid et al. [16],
who showed the efficacy of T-cell vaccination against anti-
CD4 autoimmunity in a small sample of HIV-infected
patients. Intracellular interactions of newly synthesized
CD4 molecules with various HIV proteins may be the
basis for the generation of various self-epitopes, which in
the absence of HIV are ignored due to tolerance mecha-
nisms. In fact, the formation of Env (gp160)-CD4 com-
plexes in the ER can lead to their retention via binding to
Vpu, which re-direct them to degradation [17-20]. Simi-
larly, Nef interaction with the cytoplasmic tail of mem-
brane CD4 was reported to prompt its transport to
degradation organelles [21]. Thus, autoimmunity to CD4
in HIV-1 infected patients is supported by several mecha-
nisms associated with the generation of cryptic epitopes
and to the activation of T cells not previously deleted by
central tolerance during the maturation of the T cell reper-
toire.
An alternatively, not mutually exclusive hypothesis for the
generation of anti-CD4 antibodies is the so-called "inter-
molecular help" phenomenon. This mechanism implies
that gp120-specific T cells can help antibody production
by CD4-specific B cells, which could recognize B-cell
epitopes on a gp120-CD4 complex [22]. Although the in
vivo relevance of this specific occurrence has never been
established, it should to be considered as a reasonable
possibility, reminiscent of the more general occurrence of
redirected antigen-presentation, which follows presenta-
tion of antigens complexed with antibodies with different
fine specificities [23,24]. However, this mechanism would
imply that gp120-specific immunity would necessarily
precede CD4-autoimmunity, whereas there is evidence in
contrast to this scenario [4].
3) Anti-CD4 antibodies in clinical practice: 
beyond immune suppression
As expected from basic immunology notions, anti-CD4
antibodies have long been proposed and used as immune
suppressors,  e.g., in clinical trials for the treatment of
human autoimmune diseases [25]. In early studies, anti-
CD4 mAbs were found capable to induce either cell deple-
tion [26] or functional inactivation of T cells [27,28],
although activation of T-cell functions was also
reported[29]. These divergent effects may explain the
inconsistency in the clinical efficacy of different anti-CD4
mAbs particularly in the treatment of rheumatoid arthri-
tis, namely a promising initial efficacy in open anti-CD4
trials [30,31], subsequent discouraging double-blind clin-
ical trials (reviewed in [32]), and, finally, a revitalization
of the anti-CD4 treatment notion with new, humanized
anti-CD4 mAbs [33]. Indeed, the usage of this approach
has been hampered by the complexity of its effects on the
immune system. For instance, it has long been known that
anti-CD4 monoclonals are immune suppressive or tolero-
genic depending on the circumstances of their administra-
tion [34-36]. Moreover, it is generally recognized that
non-depleting monoclonal may be relatively more effec-
tive in tolerance induction, for instance in the treatment
of rheumatoid arthritis [30], psoriasis [37], systemic lupus
erythematosus [38] and multiple sclerosis [39], although
only inconclusive and temporary symptom relief was
achieved in open studies. The fine epitope specificity of
anti-CD4 antibodies may play a role in this context, since
in rat adjuvant arthritis the developmental pattern of
arthritis differed substantially between three distinct
monoclonals, two of them preventing, the third one accel-
erating the development of the disease [40]. The effect of
each reagent on the signaling activated by CD4 via the
p56lck interacting cytoplasmic tail is supposedly impli-
cated in these differences.
In this context, the usage of human derivatives of mouse
monoclonals allowed not only to reduce the generation of
xenogeneic reactivity of rodent monoclonals, but also to
modulate induced effector mechanisms. In engineered
derivatives, the isotype used (e.g., IgG1 versus IgG4) has
implication on complement fixation capability and on
the binding to Fc receptors bearing cells, whereas varia-
tion in the number of binding sites (e.g., single chain con-
structs, Fc fragments, etc.) implies modification of
functional effects of the original reagent. Recently, a fully
human anti-CD4 monoclonal antibody (HuMax-CD4)
was tested in a multicenter, double blind, placebo-con-
trolled, randomized clinical trial on 85 moderate to severe
psoriasis patients, showing decreases in the psoriasis skin
score, although this failed to reach statistical significance
[41].
Further complexity to be considered when using in vivo
CD4-interacting reagents derives from the fact that two
sets of NFAT binding sites were identified in the HIV-1
long terminal repeat (LTR) promoter, and CD4 engage-
ment can result on the p56lck kinase dependent activation
of both cellular transcription factors and HIV-1 LTR [42].Journal of Translational Medicine 2009, 7:101 http://www.translational-medicine.com/content/7/1/101
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Thus, a signaling trigger via CD4 can activate both the
endogenous and the retroviral NFAT family of transcrip-
tion factors, simultaneously inducing both T cell activa-
tion and increased transcription of the viral genome [43].
This phenomenon was implicated to explain the observa-
tion that HIV-1-positive transplant recipients reduced
viral burden during treatment with cyclosporin A (CsA)
[44], a potent inhibitor of these transcription factors.
Moreover, CD4 dimerization occurs when CD4 mem-
brane cell density exceeds 105 per cells, involves D4-D4
domain interactions and per se triggers auto-phosphoryla-
tion and T cell activation [45].
Thus, the effect of anti-CD4 in human therapy is far from
being a straightforward immune suppression and is influ-
enced by so different factors as epitope specificity, isotype
and number of binding sites.
Recently, one anti-CD4 antibody (ibalizumab) which
does not induce any relevant immune suppressive effect in
vitro or in vivo was tested in phase II clinical trials, in the
form of human IgG4 derivative, and appeared a promis-
ing tool to block HIV-1 infection without inducing any
immunologically relevant side-effect [46,47]. This mole-
cule recognizes a CD4 D2 epitope and does not signifi-
cantly interferes with HIV-1 docking on the cell
membrane. The anti-viral activity of ibalizumab is
explained as a consequence of the interference on confor-
mational changes taking place on the cellular HIV-1
receptor at the post-binding level [48].
4) Antibodies to the CD4-gp120 complex
Following CD4-gp120 interaction, a sequence of pre-
ordered conformational changes takes place on both moi-
eties of the complex. These conformational modifications
are non-optional events, which allow gp120 interaction
with coreceptor and prompt membrane fusion and viral
entry into the cells. From the immune system perspective,
this conformational flexibility generates a series of transi-
torily expressed antigenic determinants, which re-design
the epitopic make up of interacting moieties.
Along this line, a complementary and reciprocal observa-
tion came from a recent study focused on alterations in
the antigenicity and immunogenicity of gp120 when
complexed with monoclonal antibodies specific for the
CD4 binding site of gp120 [49]. Results indicated that
these antibodies enhanced production of anti-gp120 anti-
bodies directed particularly against the V3 region[49].
These data further support the notion that immune
responses can be induced specifically against unique
epitopes created upon the interactions of CD4 with
gp120, with monoclonal antibodies, or other ligands.
The binding of gp120 to CD4 involves a well-defined site
within the first Ig-like domain of CD4 (CD4 D1) [50]. The
Phe43 CD4 residue plays a non-optional role in this cru-
cial interaction [51] by docking into a conserved hydro-
phobic pocket, a discontinuous region at the interface
between the inner and the outer domain of gp120 [52].
On the other hand, the lateral face of the D1 CD4 domain
is implicated in MHC-class II interaction, which physio-
logically provides an activation signal and plays a key role
in the physiological and pathological T lymphocyte func-
tions [53].
Notably, the OKT4A monoclonal antibody specifically
binds to the gp120 binding site of CD4, and displays, as
expected, a remarkable anti-HIV activity in vitro. However,
this reagent is also extremely immune suppressive due to
interference on the physiological CD4 function. CD4
induced (CD4i) are those epitopes, which are exposed on
the gp120 molecule after binding to the cellular receptor.
All known CD4i antibodies recognize a common, con-
served gp120 element overlapping the binding site for the
CCR5 chemokine receptor [54]. Recently, we character-
ized a gp120 neutralization epitope, recognized by the
D19 murine monoclonal antibody, which is differentially
accessible in the native HIV-1 Env according to its core-
ceptor specificity [55]. In CCR5-restricted (R5) isolates,
the D19 epitope was invariably cryptic, although it could
be exposed by the addition of soluble CD4; epitope mask-
ing was dependent on the native oligomeric structure of
Env, since it was not observed with the corresponding
monomeric gp120 molecules. By contrast, in CXCR4-
using strains, the D19 epitope was constitutively accessi-
ble. In accordance with these results, R5 isolates were
resistant to neutralization by D19, becoming sensitive
only upon addition of sCD4, whereas CXCR4-using iso-
lates were neutralized regardless of the presence of sCD4
[55]. Taken together, these observations can be deci-
phered in evolutionary term by saying that CD4-induced
changes in gp120 conformation are functionally crucial
for HIV-1 entry, and illustrates a viral strategy for seques-
tering the chemokine receptor-binding region of gp120
away from the attacks of the humoral immune response
[56].
In a reciprocal fashion, similar observations can be
applied to the CD4 receptor. Complex specific epitopes
on the CD4 moiety have been identified with partially or
totally complex-specific monoclonals antibodies, which
do not interfere with the CD4-Env complex formation,
such as CG10 [57] and antibody 55 [58], both mapping
to the second Ig-like CD4 domain. We recently generated
an anti-D2 CD4 monoclonal antibody (DB-81) [59,60]
not interfering with gp120 binding and with a binding
affinity around 700 times higher for CD4 complexed to
gp120, as compared to CD4 (Burastero S, Lusso P, et al.,
in preparation). Notably, CG10 is weakly interfering with
membrane fusion and HIV replication [57], whereas anti-
body 55 [58] and DB-81 react with both membrane-Journal of Translational Medicine 2009, 7:101 http://www.translational-medicine.com/content/7/1/101
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bound and solid-phase coated recombinant CD4 and dis-
play a broad spectrum of neutralization, suggesting that
little differences in the fine specificity may imply relevant
impact on the capability to interfere with the chain of
events which follows viral docking on the cell membrane.
A visual representation of conformation-specific epitopes
generated following CD4-gp120 interaction is depicted in
figure 1, where the binding of some of the above quoted
monoclonals is represented. In Table 1 the basic mecha-
nisms of protection by representative CD4 binding mon-
oclonals are listed.
5) Fine specificity of anti-CD4 antibodies in HIV-
1 exposed individuals with different susceptibility 
to HIV infection
It has long been known that autoimmune responses
towards CD4 detected in HIV-1 infected individuals are
produced (by the breaking of immune tolerance) which
seem to discriminate soluble versus cell associated CD4
antigens.
In fact, it was consistently reported that these antibodies
bind to solid-phase recombinant CD4, but fail to recog-
nize CD4 expressed on the surface of CD4+ lymphocytes
or cell lines [61,62](Burastero, personal observations).
These antibodies are mainly directed against a region of
the viral receptor distinct from the virus-binding domain
[63] and preferentially recognize epitopes masked by the
physiological dimerization of CD4 on the cell membrane.
This observation suggests that they are derived from such
an extensive processing of the self antigen that hidden
epitopes "emerged" on antigen presenting cells and were
exposed efficiently enough to become the target of
humoral immunity.
Consistently with these findings, extensive epitope scan-
ning mapped CD4-specific T cells in HIV-1 positive indi-
viduals to any of the four CD4 domains [64]. In contrast,
the little proportion of CD4-reacting IgG from healthy
individuals are specific for epitopes of extracellular CD4
domains (ibid.).
Recently, Denisova et al. [45] reported that immunization
of hu-CD4 C57Black/6J mice with HIV-1 gp120(451)
complexed with its receptor protein produced, in the
tolerogenic hu-CD4 transgenic background used to mimic
the human situation, two anti-CD4 monoclonal antibod-
ies, designated T6 and T9, mapping to the D3-D4
domains and recognizing soluble but not membrane
associated CD4. These antibodies were capable to com-
pete with anti-CD4 antibodies detected in HIV-1 infected
people.
In contrast to this situation, a surprise came from individ-
uals with natural resistance to HIV-1 infection. Far from
being immunologically non-reactive, these HIV-exposed,
uninfected subjects (ESN) display several unconventional
autoimmune traits, including the distinctive reactivity
towards the CD4 molecule [65]. An inter-molecular help
mechanism could explain the breaking of tolerance and
the switch to the IgG isotype of these antibodies [66]. Also
newborn babies from seropositive mothers were found to
display this autoimmune trait, which disappeared follow-
ing spontaneous viral clearance [67]. These antibodies are
likely part of a more general anti-cell immunity, including
specificities to CCR5, the HIV- coreceptor [68].
Notably, anti-CD4 antibodies in ESN subjects bind to
both membrane and soluble CD4 and have syncytium
inhibiting activity [65]. The distinct fine specificity of anti-
Table 1: MECHANISMS OF HIV-PROTECTION BY ANTI-CD4 ANTIBODIES
1) interference with gp120 binding
Antibody Binding site Binding to CD4-gp120 complex Characteristics
OKT4a[76] First CD4 domain Does not occur due to epitope masking Difficult to generate in vivo
Immune suppressive
2) interference with the sequence of conformational modifications subsequent to gp120 binding and permissive to coreceptor binding 
and membrane fusion
Antibody Binding site Binding to CD4-gp120 complex Characteristics
Ibalizumab[46] Second CD4 domain Equivalent binding to free and complexed 
CD4
Non immune suppressive
DB-81[59,60] Second CD4 domain Increased binding to complexed CD4 a) Non immune suppressive;
b) Fine specificity shared by ESN individualsJournal of Translational Medicine 2009, 7:101 http://www.translational-medicine.com/content/7/1/101
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CD4 antibodies in exposed uninfected, naturally resistant,
versus  HIV-1 infected people was later confirmed in a
larger cohort of individuals, where a clear-cut prevalence
of complex-specific antibodies in the former was reported,
suggesting a possible protective role [68]. This notion was
also supported by preliminary observations with anti-
CD4 sera form long-term non-progressor patients [69].
Thus, anti-CD4 antibodies in ESN subjects are one among
several signs of unconventional immunity, which were
described in HIV-1 resistant individuals [70]. We specu-
late that specificity to the first two domains of membrane
CD4, with particular reference to strictly conformation-
dependent epitopes, and including those, which are pref-
erentially expressed after gp120 binding may be associ-
ated with a non-harmful and potentially protective
humoral anti-HIV-1 autoimmune response.
Further studies are needed to characterize anti-CD4 anti-
bodies fine specificities in healthy subjects, with or with-
out HIV- exposure, and to determine their HIV-1
inhibitory capability.
Molecular structure analysis of free versus unbound CD4
may be helpful in shedding light on the above reported
observations. Here, the two structures backbones were
aligned and they resulted to be almost completely over-
lapping (Root Mean Square Distance < 0.7 Å). C-alpha
atoms B-factors were then extracted from the PDB files of
the compared structures (accession numbers 3CD4 and
2NXY for CD4 and CD4-gp120 complex, respectively) as
a measure of local backbone mobility [71](Figure 2). The
first CD4 domain did not display significant variations of
local backbone mobility with the expected exception of
the region in close contact with the surface of gp120. In
contrast, the second domain displayed large variations
which mapped the majority of the structure (Figure 3).
This result suggests that the D2 CD4 domain significantly
reduces its local flexibility, despite the fact that it is not
directly involved in binding, whereas the D1 CD4 domain
remains virtually unaltered in its local mobility. Thus, it
appears that the conformation of the membrane molecule
serving as viral receptor has a defined degree of flexibility
of solvent-exposed determinants, which is decreased fol-
lowing ligand binding. This decrease occurs not only, as
expected, in the direct proximity of the binding site, but
also in extended portions of the second CD4 domain.
In order to further highlight these local differences, in fig-
ure 4 the variations of dihedral angles (Φ and Ψ) between
the bound and the free state are plotted against the single
residues whose local geometry is influenced by the bind-
ing of the two moieties.
The pheomenon of complex-dependent conformational
variations may be exploited to augment the chances of
inhibiting viral entry by increasing the opportunity for
Schematic representation of the interaction between CD4  and gp120, with reference to the formation of new epitopes Figure 1
Schematic representation of the interaction between 
CD4 and gp120, with reference to the formation of 
new epitopes. The indicated monoclonal antibodies are 
either exclusively (CG10) or preferentially (DB-81) binding 
to CD4 complexed to gp120 (right part of the figure), as 
compared to CD4 only (left part of the figure). Similarly, the 
anti-gp120 D19 monoclonal antibody is represented, which 
binds with higher affinity to gp120 complexed to CD4, as 
compared to (R5-coreceptor restricted) gp120 only. The 
affinities of the antigen-antibody interactions are propor-
tional to the thickness of the arrow pointing to the epitope.
B factors (as a measure of local backbone mobility, on the y- axys) of C-alpha atoms for the free (gray) and the gp120- complexed (red) CD4 protein (C-alpha residue numbering is  on the x-axis, according to UniProtKB/Swiss-Prot P01730).  The first Ig-like V-type (residues 26 -- 125) and the second Ig- like C2-type 1 (residues 126 -- 203) were included in this  analysis Figure 2
B factors (as a measure of local backbone mobility, 
on the y-axys) of C-alpha atoms for the free (gray) 
and the gp120-complexed (red) CD4 protein (C-
alpha residue numbering is on the x-axis, according 
to UniProtKB/Swiss-Prot P01730).The first Ig-like V-type 
(residues 26 -- 125) and the second Ig-like C2-type 1 (resi-
dues 126 -- 203) were included in this analysis. Data were 
calculated from PDB files 3CD4 and 2NXY for free and com-
plexed CD4, respectively. The third and forth domains were 
not considered due to the expected influence on B factors of 
these portions of the molecule by physiological CD4 dimeri-
zation.Journal of Translational Medicine 2009, 7:101 http://www.translational-medicine.com/content/7/1/101
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binding to occur by strictly conformational antibodies, or
derivatives thereof, specific to such protruding "stiffer"
epitopes. Since such a locally rigid antigenic make up is by
definition transient, and the corresponding set of epitope
is limited, it may be in principle associated with an overall
lower immunogenicity. However, available data on anti-
CD4 antibodies in ESN demonstrate that a proportion of
individuals can indeed spontaneously produce antibodies
with these fine specificities. These may pre-exist as the
results of previous exposure to different (non HIV-related)
antigenic stimuli, they may be natural antibodies with rel-
atively low affinilty, and/or may be subjected to affinity
maturation following HIV-1 exposure. The propensity to
assume a different conformation as compared to the
native one was also found associated to increased immu-
nogenicity and antibody affinity in immunization experi-
ments performed with CCR5-ECL-1 loop after alanine
substitution [72]. In that context, this finding led us to
hypothesize that flexibility of some conformed regions
can change their status upon antigenic stimuli and prove
helpful in enhancing immunogenicity and eliciting high
affinity HIV protective antibodies.
Regions of CD4 structure (within the first and the second  CD4 domain) that display (in red) the greatest changes in C- alpha B factor between the free form and the one complexed  with gp120 Figure 3
Regions of CD4 structure (within the first and the 
second CD4 domain) that display (in red) the great-
est changes in C-alpha B factor between the free 
form and the one complexed with gp120. The C-alpha 
B-factor was calculated as a measure of local backbone flexi-
bility.
Local differences in the conformation of CD4 in the gp120-bound versus free state Figure 4
Local differences in the conformation of CD4 in the gp120-bound versus free state. Absolute variations of dihedral 
backbone angles Φ (upper panel) ad Ψ (lower panel) between bound and free CD4 structure are plotted on the y-axis against 
the single residues (on the x-axis) whose local geometry is influenced by the interaction between the two moieties.Journal of Translational Medicine 2009, 7:101 http://www.translational-medicine.com/content/7/1/101
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Conclusion
Individuals naturally resistant to HIV-1 infection repre-
sent an experiment of nature whose study has potential
implication for the design of alternative immunological
therapies of HIV-1 infection. Anti-CD4 antibodies are not
subjected to the immune evasion, which characterize Env-
specific immunity, nor to the generation of resistance,
which impairs the efficacy of antiretroviral therapy with
non-entry inhibitors. Thus, the possibility to elicit non-
immune suppressive, protective anti-CD4 immune
responses or, alternatively, to use monoclonal antibodies
or derivatives thereof, which will reproduce this activity
may dramatically improve therapeutic options for HIV-1
treatment in the next few years.
A long-standing effort has been attempted to target con-
formation-specific epitopes, as a strategy to overcome the
failure of conventional vaccination approaches to prevent
HIV-1 infection [73-75]. The data we review here suggest
that the fine characterization of crucial epitopes recog-
nized by antibodies from ESN subjects will allow to
increase the chances to successfully implement this strat-
egy
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